Anthrax Vaccine Protects Monkeys
News Jun 28, 2016
These results indicate that anthrax capsule is a highly effective vaccine component that should be considered for incorporation in future generation anthrax vaccines.
Bacillus anthracis, the bacterium that causes anthrax, is recognized as one of the most significant bioterrorism threats. It produces three main components that allow it to cause disease—lethal toxin, edema toxin, and capsule. During anthrax infection, the bacterium invades and grows to high concentrations in the host. The capsule surrounds the bacterium and prevents it from being ingested and destroyed by the white blood cells, thus allowing anthrax infection to progress. The toxins are thought to act mainly by damaging the body’s natural defense mechanisms.
Current human vaccines for anthrax are based on the protective antigen component of the anthrax toxins. Scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have extensively studied protective antigen, demonstrating that protective antigen alone confers protection in animal challenge studies with both rabbits and monkeys.
However, according to senior author Arthur M. Friedlander, M.D., of USAMRIID, concerns about reliance on a single antigen—as well as the issue of protecting against anthrax strains that may be vaccine resistant—have prompted the search for additional vaccine components. Bacterial capsules are commonly used in licensed vaccines for other diseases, including certain types of pneumonia and meningitis.
Friedlander’s group had already demonstrated in published studies that the anthrax capsule plays a role in conferring protection. In their current work, the team describes testing a higher dose of the capsule vaccine in monkeys against a lethal aerosol challenge with anthrax spores. All the animals receiving the capsule vaccine survived while all non-vaccinated animals succumbed to the disease.
“In the 140-year history of research on anthrax there have been two previous types of vaccine, the last one licensed in 1970,” Friedlander said. “This new capsule vaccine is expected to work against possible vaccine-resistant strains of anthrax and to protect individuals who may not respond optimally to protective antigen alone. In addition, it could be combined with protective antigen to create a multi-component vaccine that may enhance the efficacy of protective antigen- based vaccines.”
Combining Different Malaria Vaccines Could Reduce Cases by 91%News
Using two experimental anti-malarial vaccines, which work in different ways, can greatly reduce the number of malaria infections in animal studies. Experimental vaccines, which independently achieve 48% and 68% reductions in malaria cases, can achieve 91% reduction when combined.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE